NHLBI TOPMed: Childhood Asthma Management Program (CAMP)

The Childhood Asthma Management Program (CAMP) was designed to evaluate whether continuous, long-term treatment (over a period of four to six years) with either an inhaled corticosteroid (budesonide) or an inhaled noncorticosteroid drug (nedocromil) safely produces an improvement in lung growth as compared with treatment for symptoms only (with albuterol and, if necessary, prednisone, administered as needed). The primary outcome in the study was lung growth, as assessed by the change in forced expiratory volume in one second (FEV1, expressed as a percentage of the predicted value) after the administration of a bronchodilator. Secondary outcomes included the degree of airway responsiveness, morbidity, physical growth, and psychological development.]]>
TOPMed Whole Genome Sequencing Methods: Freeze 9TOPMed Whole Genome Sequencing Methods: Freeze 10CAMP (Childhood Asthma Management Program): Inclusion Criteria Aged 5 to 12 years at time of screening Chronic asthma as evidenced by one or more of the following historical findings for at least 6 months in the year prior to interview: Asthma symptoms at least two times per week At least two usages per week of an inhaled bronchodilator Daily asthma medication Completion of a screening period (28 days) providing evidence of mild to moderate asthma as defined by criteria (see Table 2 in PMID: 10027502) Methacholine reactivity: FEV1 PC20 no greater than 12.5 mg/mL Consent of parent or guardian Assent of child Ability to comply with trial for 5 to 6 years Exclusion Criteria Severe asthma as evidenced by one or more of the following historical findings: Two or more hospitalizations for asthma in the year prior to screening Six or more steroid bursts in the year prior to screening Intubation for asthma at any time in the past Presence of one or more of the following confounding or complicating conditions: Other active pulmonary disease Pulmonary function suggesting a ventilatory defect or evidence of irreversible lung disease Severe chronic sinusitis or nasal polyposis Introduction of, or a change in, allergen immunotherapy in the month prior to interview Use of more than four sprays of nasal steroids daily (only beclomethasone allowed) at the time of randomization Current use of cimetidine, metoclopramide, ranitidine, or other treatment for gastroesophageal reflux Participation in another pharmaceutical, immunotherapy, respiratory, or asthma study Pregnancy Inability to perform acceptable spirometry Inability to complete the methacholine challenge Evidence that the patient or family might be noncompliant or might move from the clinic area before completion of follow-up ]]>